Free standard shipping for orders over $200.

Blog

September 2026

Decorative Thymosin Alpha 1 research title card

Clinicians: Thymosin Alpha 1 Reduced Infections in 706 Patients

Thymosin alpha 1 (Tα1) is a synthetic immune modulator with the strongest clinical support in severe acute pancreatitis, where trial data link it to fewer extrapancreatic infections and better CD4+ T cell counts, along with promising but less conclusive evidence in viral hepatitis and cancer treatment support. Evidence quality varies sharply by condition, and dosing, timing, and patient selection all shape outcomes. Anyone considering Tα1 for a specific health condition should talk to a physician familiar with immunomodulatory therapy before starting.

DSIP dosing guidance title card

Avoid DSIP Dosing Errors: Start 50–100 mcg, Cap 250 mcg

Most sleep-focused protocols start DSIP at 50 to 100 micrograms subcutaneously, dosed 30 to 60 minutes before bed, within a broader community range of 50 to 400 micrograms. Human research on this peptide is thin, mostly intravenous, and decades old, and no FDA-approved DSIP product exists, so treat these numbers as a starting framework for a conversation with a prescriber, not a fixed prescription.

 


Do you want to hide this popup?

Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare
Shopping cart close